- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01313624
Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis (AIR-BX1)
March 7, 2014 updated by: Gilead Sciences
A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution in Subjects With Non-CF Bronchiectasis and Gram-Negative Endobronchial Infection
The AIR-BX1 study enrolled people with non-cystic fibrosis (non-CF) bronchiectasis and gram-negative airway infection.
Participants received two 28-day courses of either Aztreonam for Inhalation Solution (AZLI) or placebo taken 3 times a day.
Each course was followed by a 28-day off-drug period.
Following the two blinded courses, all participants received a 28-day course of open-label AZLI then were followed for an additional 56 days.
Study Overview
Study Type
Interventional
Enrollment (Actual)
266
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New South Wales
-
Concord, New South Wales, Australia, 2139
- Concord Hospital
-
Darlinghurst, New South Wales, Australia, 2010
- St. Vincent's Hospital
-
Glebe, New South Wales, Australia, 2037
- Woolcock Institute of Medical Research
-
Kogarah, New South Wales, Australia, 2217
- St. George Hospital
-
Perth, New South Wales, Australia, 6000
- Royal Perth Hospital
-
Westmead, New South Wales, Australia, 2145
- Westmead Hospital
-
-
Queensland
-
Brisbane, Queensland, Australia, 4101
- Mater Adult Hospital
-
Chermside, Queensland, Australia, 4032
- The Prince Charles Hospital
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Royla Adelaide Hospital
-
Daws Park, South Australia, Australia, 5041
- Repatriation General Hospital
-
Toorak Gardens, South Australia, Australia, 5065
- Respiratory Clinical Trials
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Monash Medical Centre
-
Frankston, Victoria, Australia, 3199
- Peninsula Health
-
Westmead, Victoria, Australia, 3194
- Alfred Hospital
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Sir Charles Gairdner Hospital
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4N1
- University of Calgary
-
Edmonton, Alberta, Canada, T6G 2C8
- University of Alberta
-
-
British Columbia
-
Kelowna, British Columbia, Canada, V1W 1V3
- Kelowna Respiratory and Allergy Clinic
-
Vancouver, British Columbia, Canada, V5Z 1M9
- The Lung Centre at Vancouver General Hospital
-
Vancouver, British Columbia, Canada, V6Z 1Y6
- St. Paul's Hospital Pacific Lung Research
-
-
Ontario
-
Kingston, Ontario, Canada, K7L 2V6
- Kingston General Hospital / Queen's University
-
Toronto, Ontario, Canada, M5B 1W8
- St. Michael's Hospital
-
Windsor, Ontario, Canada, N8X 5A6
- Dr. Anil Dhar Private Practice
-
-
Quebec
-
Montreal, Quebec, Canada, H2W 1T8
- Centre Hospitalier de L'Université de Montréal Hotel Dieu
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85006
- Pulmonary Associates
-
Phoenix, Arizona, United States, 85012
- Arizona Pulmonary Specialists, Ltd
-
Phoenix, Arizona, United States, 85013
- St. Joseph's Hospital and Medical Center Heart and Lung Institute
-
Scottsdale, Arizona, United States, 85258
- Arizona Pulmonary Specialists
-
-
California
-
Los Angeles, California, United States, 90095
- David Geffen School of Medicine at UCLA
-
Sacramento, California, United States, 95817
- UC Davis Medical Center Division of Pulmonary, Critical Care and Sleep Medicine
-
Ventura, California, United States, 93003
- Landon Pediatric Foundation
-
-
Colorado
-
Denver, Colorado, United States, 80202
- National Jewish Health
-
-
Connecticut
-
Farmington, Connecticut, United States, 06030
- University of Connecticut Health Center
-
-
Florida
-
Clearwater, Florida, United States, 33756
- Bay Area Chest Physicians
-
Gainesville, Florida, United States, 32610
- University of Florida
-
Kissimmee, Florida, United States, 34741
- Pulmonary Disease Specialists (PDS) Research
-
Miami, Florida, United States, 33136
- University of Miami - Miller School of Medicine
-
Orlando, Florida, United States, 32803
- Central Florida Pulmonary Group
-
Weston, Florida, United States, 33331
- Cleveland Clinic Florida
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Atlanta Pulmonary Group
-
-
Maryland
-
Baltimore, Maryland, United States, 21204
- Pulmonary and Critical Care Associates of Baltimore
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Missouri
-
Chesterfield, Missouri, United States, 63017
- Cardio Pulmonary Research at St. Luke's Hospital
-
-
New York
-
Albany, New York, United States, 12208
- Albany Medical Center
-
Jamaica, New York, United States, 11418
- Jamaica Hospital Medical Center
-
Mineola, New York, United States, 11501
- Winthrop University Hospital - Clinical Trials Center
-
New York, New York, United States, 10019
- St. Luke's Roosevelt Hospital
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- University of Cincinnati / UC Health
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health and Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19102
- Drexel University College of Medicine
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania Medical Center - Pulmonary, Allergy & Critical Care Division
-
Philadelphia, Pennsylvania, United States, 19107
- Asthma Allergy & Pulmonary Associates
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Texas
-
McKinney, Texas, United States, 75069
- Metroplex Pulmonary and Sleep Center
-
San Antonio, Texas, United States, 78212
- Alamo Clinical Research Associates
-
Tyler, Texas, United States, 75708
- University of Texas Health Science Center at Tyler
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- University of Virginia Pulmonary and Critical Care
-
Falls Church, Virginia, United States, 22042
- Inova Fairfax Hospital/ Heart and Vascular Institute Advanced Lung Disease and Transplant Center
-
-
Washington
-
Seattle, Washington, United States, 98104
- Swedish Medical Center/Minor James Clinic
-
Tacoma, Washington, United States, 98405
- Multicare Pulmonary Specialist
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male/Female 18 years or older with non-CF bronchiectasis
- Chronic sputum production on most days
- Positive sputum culture for gram-negative organisms
- Must have met lung function requirements
Exclusion Criteria:
- History of CF
- Hospitalized within 14 days prior to joining the study
- Previous exposure to AZLI
- Pregnant, breastfeeding, or unwilling to follow contraceptive measures for the study
- Must have met liver and kidney function requirements
- Continuous oxygen use of greater than 2 liters per minute (supplemental oxygen with activity and at night was allowed)
- Treatment for nontuberculous mycobacteria infection or active mycobacterium tuberculosis infection within 1 year of enrollment
- Other serious medical conditions.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AZLI-AZLI
Participants were randomized to receive blinded AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.
|
AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily
|
Placebo Comparator: Placebo-AZLI
Participants were randomized to receive blinded placebo to match AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.
|
AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily
Placebo to match AZLI administered via nebulizer three times daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in QOL-B Respiratory Symptoms Score at Day 28
Time Frame: Baseline to Day 28
|
The mean (SD) change in the Respiratory Symptoms score on the Quality of Life Questionnaire-Bronchiectasis (QOL-B) was measured from baseline to the end of Course 1 (Day 28).
The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life.
|
Baseline to Day 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in QOL-B Respiratory Symptoms Score at Day 84
Time Frame: Baseline to Day 84
|
The mean (SD) change in the Respiratory Symptoms score on the QOL-B was measured from baseline to the end of Course 2 (Day 84).
The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life.
|
Baseline to Day 84
|
Time to Protocol-Defined Exacerbation (PDE)
Time Frame: Baseline to Day 112
|
Protocol-defined exacerbation was defined as an acute worsening of respiratory disease that triggered the initiation of a non-study antibiotic meeting at least 3 major criteria, or 2 major and at least 2 minor criteria.
|
Baseline to Day 112
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Alan Barker, MD, Oregon Health and Science University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2011
Primary Completion (Actual)
March 1, 2013
Study Completion (Actual)
June 1, 2013
Study Registration Dates
First Submitted
March 10, 2011
First Submitted That Met QC Criteria
March 11, 2011
First Posted (Estimate)
March 14, 2011
Study Record Updates
Last Update Posted (Estimate)
April 16, 2014
Last Update Submitted That Met QC Criteria
March 7, 2014
Last Verified
March 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GS-US-219-0101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bronchiectasis
-
Ruijin HospitalAstraZeneca Investment (China) Co., LtdNot yet recruitingBronchiectasis AdultChina
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Fondazione Policlinico Universitario Agostino Gemelli IRCCS; IRCCS Azienda... and other collaboratorsActive, not recruiting
-
University of Sao Paulo General HospitalEnrolling by invitation
-
University of Sao Paulo General HospitalFundação de Amparo à Pesquisa do Estado de São PauloCompletedBronchiectasis AdultBrazil
-
University of North Carolina, Chapel HillCompletedBronchiectasis AdultUnited States
-
Seoul National University Bundang HospitalUnknownSymptomatic BronchiectasisKorea, Republic of
-
Chang Gung Memorial HospitalNot yet recruitingBronchiectasis AdultTaiwan
-
Shanghai Pulmonary Hospital, Shanghai, ChinaNot yet recruitingBronchiectasis Adult
-
University of DundeeRecruitingBronchiectasis AdultUnited Kingdom
-
Papworth Hospital NHS Foundation TrustGlaxoSmithKlineCompletedBronchiectasis | Idiopathic BronchiectasisUnited Kingdom
Clinical Trials on AZLI
-
Gilead SciencesCompleted
-
Gilead SciencesCompletedBronchiectasisUnited States, Belgium, Spain, Canada, Australia, Germany, United Kingdom, Netherlands, France, Italy
-
Gilead SciencesCompleted
-
Gilead SciencesCovance; ClinPhone, Inc.; Chiltern International Inc.CompletedCystic FibrosisBelgium, France, Germany, Italy, Netherlands, Spain, United States, Ireland, United Kingdom, Portugal, Austria, Denmark, Switzerland
-
Gilead SciencesCompletedCystic Fibrosis | Pseudomonas AeruginosaSpain, United States, Germany, France, Italy, Poland
-
Gilead SciencesTerminatedCystic Fibrosis | Pseudomonas Aeruginosa Respiratory Tract Infection/ColonizationUnited States, Spain, United Kingdom, Denmark, Belgium, France, Italy, Germany, Israel, Netherlands, Austria, Greece
-
Gilead SciencesCompletedCystic Fibrosis | Burkholderia InfectionsUnited States, Canada
-
Gilead SciencesCompletedBronchiectasisUnited States
-
Gilead SciencesCompletedCystic FibrosisUnited States, Canada, Australia, New Zealand
-
Gilead SciencesCompletedCystic FibrosisUnited States, France, Spain, Germany, Austria, Belgium, Italy, Netherlands, Poland